Omnicell (NASDAQ:OMCL) EVP Corey Manley Sells 6,106 Shares

Omnicell, Inc. (NASDAQ:OMCL) EVP Corey Manley sold 6,106 shares of the business’s stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $49.90, for a total value of $304,689.40. Following the completion of the transaction, the executive vice president owned 91,674 shares of the company’s stock, valued at $4,574,532.60. This represents a 6.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Omnicell Stock Performance

Shares of Omnicell stock traded up $0.45 during trading on Monday, hitting $51.19. 386,519 shares of the company’s stock traded hands, compared to its average volume of 547,772. Omnicell, Inc. has a 1 year low of $22.66 and a 1 year high of $51.30. The business has a 50-day simple moving average of $41.06 and a 200-day simple moving average of $34.32. The stock has a market capitalization of $2.30 billion, a P/E ratio of 119.05, a PEG ratio of 5.40 and a beta of 0.77. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.44 and a quick ratio of 1.21.

Institutional Investors Weigh In On Omnicell

A number of institutional investors and hedge funds have recently bought and sold shares of OMCL. Dimensional Fund Advisors LP boosted its stake in shares of Omnicell by 9.1% in the third quarter. Dimensional Fund Advisors LP now owns 2,364,068 shares of the company’s stock worth $71,985,000 after acquiring an additional 197,462 shares during the period. Lazard Asset Management LLC grew its holdings in Omnicell by 3.8% during the 2nd quarter. Lazard Asset Management LLC now owns 1,708,345 shares of the company’s stock valued at $50,225,000 after buying an additional 62,733 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. raised its position in shares of Omnicell by 1.3% during the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,423,604 shares of the company’s stock valued at $41,854,000 after buying an additional 17,680 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Omnicell by 2.6% during the second quarter. Geode Capital Management LLC now owns 1,195,896 shares of the company’s stock valued at $35,163,000 after buying an additional 30,678 shares during the last quarter. Finally, Millennium Management LLC purchased a new position in shares of Omnicell in the third quarter worth $25,625,000. 97.70% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on OMCL. KeyCorp raised shares of Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price objective for the company in a report on Wednesday. Zacks Research cut Omnicell from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 9th. Wells Fargo & Company raised their price target on Omnicell from $43.00 to $52.00 and gave the stock an “overweight” rating in a research note on Monday, January 5th. Benchmark raised their price objective on shares of Omnicell from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Omnicell in a report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $47.83.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.